Literature DB >> 9597141

The role of complement and complement receptors in induction and regulation of immunity.

M C Carroll1.   

Abstract

Covalent attachment of activated complement C3 (C3d) to antigen links innate and adaptive immunity by targeting antigen to follicular dendritic cells (FDC) and B cells via specific receptors CD21 and CD35. Recent characterization of knockout mice deficient in complement components C3, C4, or the receptors CD21 and CD35 as well as biochemical studies of the CD21/CD19/Tapa-1 coreceptor on B cells have helped to elucidate the mechanism of complement regulation of both B-1 and B-2 lymphocytes. Interestingly, natural antibody of the adaptive immune system provides a major recognition role in activation of the complement system, which in turn enhances activation of antigen-specific B cells. Enhancement of the primary and secondary immune response to T-dependent antigens is mediated by coligation of the coreceptor and the B cell antigen receptor, which dramatically increases follicular retention and B cell survival within the germinal center. Most recent evidence suggests that complement also regulates elimination of self-reactive B cells, as breeding of mice that are deficient in C4 or CD21/CD35 with the lupus-prone strain of lpr mice demonstrates an exacerbation of disease due to an increase in autoantibodies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9597141     DOI: 10.1146/annurev.immunol.16.1.545

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  140 in total

1.  The influence of complement receptor type 1 (CD35) and decay-accelerating factor (CD55) on complement receptor type 2- (CD21) mediated alternative pathway activation by B cells.

Authors:  R G Leslie
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

2.  Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM.

Authors:  M Boes; T Schmidt; K Linkemann; B C Beaudette; A Marshak-Rothstein; J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

3.  Reduced expression of the complement receptor type 2 (CR2, CD21) by synovial fluid B and T lymphocytes.

Authors:  H Illges; M Braun; H H Peter; I Melchers
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 4.  Functions of antibodies in the regulation of B cell responses in vivo.

Authors:  B Heyman
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 5.  Studies of the humoral immune response.

Authors:  G Kelsoe
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

Review 6.  Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis.

Authors:  J E Salmon; G Girardi; V M Holers
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 7.  Complement in central nervous system inflammation.

Authors:  Scott R Barnum
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

8.  The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models.

Authors:  Masha Fridkis-Hareli; Michael Storek; Eran Or; Richard Altman; Suresh Katti; Fang Sun; Tao Peng; Jeff Hunter; Krista Johnson; Yi Wang; Ante S Lundberg; Gaurav Mehta; Nirmal K Banda; V Michael Holers
Journal:  Mol Immunol       Date:  2018-12-01       Impact factor: 4.407

9.  Homozygous hereditary C3 deficiency due to a premature stop codon.

Authors:  Edimara Da Silva Reis; Gisele Vanessa Baracho; Adriana Sousa Lima; Chuck S Farah; Lourdes Isaac
Journal:  J Clin Immunol       Date:  2002-11       Impact factor: 8.317

10.  Complement and dilated cardiomyopathy: a role of sublytic terminal complement complex-induced tumor necrosis factor-alpha synthesis in cardiac myocytes.

Authors:  Thomas P Zwaka; Dimitar Manolov; Cüneyt Ozdemir; Nikolaus Marx; Ziya Kaya; Matthias Kochs; Martin Höher; Vinzenz Hombach; Jan Torzewski
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.